Welcome, Guest. Please login or register.
June 06, 2023, 01:30:20 am

Login with username, password and session length

  • Total Posts: 55098
  • Total Topics: 4847
  • Online Today: 37
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 19
Total: 19


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Hep C Combo Cures Most People Coinfected With HIV  (Read 4380 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
New Hep C Combo Cures Most People Coinfected With HIV
« on: July 31, 2017, 10:08:37 am »
AbbVie’s new Maviret (glecaprevir/pibrentasvir) coformulation taken for 8 or 12 weeks led to a sustained response in almost all HIV-positive people with hepatitis C in the EXPEDITION-2 study, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) taking place this week in Paris.

Maviret demonstrated an overall cure rate of 98 percent, and all study participants without liver cirrhosis were cured with an eight-week course of therapy, reported Karine Lacombe, MD, of Saint-Antoine Hospital in Paris.

For more...


© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.